SEGMENT INFORMATION

9 Months Ended

Jun. 30, 2013

SEGMENT INFORMATION [Abstract]

SEGMENT INFORMATION

6. SEGMENT INFORMATION

We operate in two principal segments - research services and research products. Our Services segment provides research and development support on a contract basis directly to pharmaceutical companies. Our Products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers and medical research institutions. Our accounting policies in these segments are the same as those described in the summary of significant accounting policies found in Note 2 to Consolidated Financial Statements in our annual report on Form 10-K/A for the year ended September 30, 2012.

	Three Months Ended June 30						Nine Months Ended June 30,
	2013			2012			2013			2012
				(Restated)						(Restated)
Revenue:
Service	$	4,156		$	5,200		$	12,493		$	16,090
Product		1,444			1,986			4,067			5,578
	$	5,600		$	7,186		$	16,560		$	21,668
Operating income (loss):
Service	$	222		$	(668	)	$	71		$	(3,367	)
Product		216			227			661			(70	)
Corporate		-			(99	)		-			(110	)
	$	438		$	(540	)	$	732		$	(3,547	)
Interest expense		(163	)		(172	)		(492	)		(540	)
Change in fair value of warrant liability - decrease		318			458			293			458
Other income		1			8			6			8
Income (loss) before income taxes	$	594		$	(246	)	$	539		$	(3,621	)

Restructuring costs of $524 and $99 are included in the operating losses for the three months ended June 30, 2012 for the Service and Corporate segments, respectively. Restructuring costs of $577 and $110 are included in the operating losses for the nine months ended June 30, 2012 for the Service and Corporate segments, respectively.